Jazz Pharmaceuticals (JAZZ) Institutional Ownership
13F filers reported holding 51.7% of Jazz Pharmaceuticals (JAZZ) shares as of Sep 30, 2026, across 463 filers.
- Held by 13F filers
- 51.7%
- Sep 30, 2026
- 13F filers
- 463
- quarter ended Sep 30, 2026
- 13F value
- $7.7B
- 33.2M shares
- Quarter's fund flow
- Mild accumulation
- 78 new · 43 closed
Is the smart money (institutions and insiders) accumulating or distributing? One lagging input, not a buy signal.
| Date | Name | Role | Type | Shares | Price** | SEC filing |
|---|---|---|---|---|---|---|
| Nov 6, 2026 | COZADD BRUCE C | director | Acquired · Option exercise | 734 | $136.18 | ↗ |
| Nov 6, 2026 | COZADD BRUCE C | director | Acquired · Option exercise | 85,766 | $136.18 | ↗ |
| Nov 6, 2026 | COZADD BRUCE C | director | Disposed · Open-market sale | 27,714 | $234.91 | ↗ |
| Nov 6, 2026 | COZADD BRUCE C | director | Disposed · Open-market sale | 10,688 | $235.82 | ↗ |
| Nov 6, 2026 | COZADD BRUCE C | director | Disposed · Open-market sale | 24,483 | $236.84 | ↗ |
| Nov 6, 2026 | COZADD BRUCE C | director | Disposed · Open-market sale | 5,923 | $237.39 | ↗ |
| Nov 6, 2026 | COZADD BRUCE C | director | Disposed · Option exercise | 734Incentive Stock Option (right to buy) | — | ↗ |
| Nov 6, 2026 | COZADD BRUCE C | director | Disposed · Option exercise | 85,766Non-Qualified Stock Option (right to buy) | — | ↗ |
| Nov 4, 2026 | Carr Patricia | SVP, Chief Accounting Officer | Acquired · Option exercise | 1,250 | $140.03 | ↗ |
| Nov 4, 2026 | Carr Patricia | SVP, Chief Accounting Officer | Disposed · Open-market sale | 1,250 | $231.37 | ↗ |
| Nov 4, 2026 | Carr Patricia | SVP, Chief Accounting Officer | Disposed · Open-market sale | 163 | $231.27 | ↗ |
| Nov 4, 2026 | Carr Patricia | SVP, Chief Accounting Officer | Disposed · Option exercise | 1,250Non-Qualified Stock Option (right to buy) | — | ↗ |
| Nov 3, 2026 | GALA RENEE D | President & CEO | Disposed · Open-market sale | 1,000 | $225.37 | ↗ |
| Nov 2, 2026 | COZADD BRUCE C | director | Disposed · Open-market sale | 6,000 | $215.84 | ↗ |
| Oct 6, 2026 | GALA RENEE D | President & CEO | Disposed · Open-market sale | 2,000 | $236.40 | ↗ |
| Oct 1, 2026 | COZADD BRUCE C | director | Disposed · Open-market sale | 6,000 | $230.33 | ↗ |
| Sep 10, 2026 | Patil Neena M | EVP & Chief Legal Officer | Disposed · Open-market sale | 1,200 | $240.94 | ↗ |
| Sep 8, 2026 | Henderson Mary Elizabeth | SVP, Technical Operations | Disposed · Tax withholding | 1,412 | $243.03 | ↗ |
| Sep 8, 2026 | Henderson Mary Elizabeth | SVP, Technical Operations | Disposed · Tax withholding | 15 | $241.20 | ↗ |
| Sep 8, 2026 | GALA RENEE D | President & CEO | Disposed · Tax withholding | 1,967 | $246.81 | ↗ |
* Holdings as reported for Sep 30, 2026, 49 days old; funds file up to 45 days after each quarter-end, so the newest complete quarter runs 45 to 135 days behind.
** A price of “—” marks an option exercise, RSU vest or a filing without a usable per-share price, not a $0 trade.
Common questions
How much of Jazz Pharmaceuticals do institutions hold?
13F filers reported holding 51.7% of Jazz Pharmaceuticals' shares as of Sep 30, 2026, across 463 filers.
How many 13F filers hold Jazz Pharmaceuticals?
Jazz Pharmaceuticals was held by 463 13F filers as of Sep 30, 2026.
Not investment advice.

